Navitas Lifesciences proudly presents webinar on Risk Mitigation in Gene Therapy Clinical Trial Development. The webinar will include key challenges and issues related to
- Optimum Patient Population: Stratification factors to be considered (clinical phenotypes supported by imaging/ biochemical/structural or morphological evidence)
- Exclusion based on pre-existing neutralising antibodies
- DSMB considerations in gene therapy clinical trials
- Adverse Events of Special Interest: Immunogenicity, Insertional mutagenesis, off target effects
- Patient centricity and retention in gene therapy trials
Speakers
Dr. Narendra Chirmule CEO SymphonyTech | |
Dr. Kirk Hammond Professor of Medicine, UC San Diego and Founder Renova Therapeutics | |
Dr. Atul Gupta Associate Vice President, Medical and Scientific Affairs Navitas Life Sciences |
Live Webinar | Thursday 09, December 2021 Time: 10:00am – 11:00am EST |
© 2021 Navitas Life Sciences | Privacy Policy